Tagged with Generic

Pricing Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr.  of the Association for Accessible Medicines (AAM) reveals the data behind generic competition and elaborates on opportunities for further savings.    The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs—a growing category…

USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…

Egypt Dr Hany Mashaal, general manager for Egypt and the Rest of Middle East for Sun Pharma, explains the importance of Egypt for the Indian company, having recently opened a manufacturing facility in the country. He highlights the need for a faster drug registration process and gives an outlook at the…

China The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both countries and regulatory reform underway in China, Indian firms are jumping at the chance to bring their competitively-priced drugs to…

Taiwan Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to share the company’s transition strategy to leverage their innovative development platforms and manufacturing capabilities to be a partner of choice…

Opinion Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars.   Savings have totaled…

Egypt Dr Mohamed Mabrouk, CEO of Pharmed Healthcare, highlights how the company has evolved from only offering Hepatitis C treatment to having 112 products in the pipeline today. He also emphasises the importance of local companies for the government’s 100 Million Seha campaign, while outlining Pharmed’s future strategy including commercial partnerships…

Spain Lab Seid is a family owned pharmaceutical company based in Barcelona, specialising in branded out of patent products in the field of women’s health. Seid’s general manager, Joaquín Vilá, discusses the turnaround of the company since taking over in 2011, and the strategy behind its consolidation around gynaecology. Vila also…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…

France Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital sector, and its future growth strategies.   Generics companies need a wide portfolio to meet all of the generics needs…

France Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in connecting the health network around patient needs. De Lavenne also shares his view on the French pharmaceutical market and the…